



UN EBOLA RESPONSE MPTF
PROJECT QUARTERLY PROGRESS REPORT - VERSION 1
Period (Quarter-Year): 2016 (including activities between February and August, 2016)

Project Number and Title: #54 & #57 - Vaccination Cohort Study: Preventing late transmission of Ebola from survivors to close contacts – Phase I and Phase II This report covers both Phase 1 & Phase 2 of Vaccine Cohort Study	PROJECT START DATE¹: 23-02-2016 (Phase I) 01-04-2016 (Phase II)	AMOUNT ALLOCATED by MPTF \$ 299,547 (Phase I) \$1,199,603 (Phase II)	RECIPIENT ORGANIZATION World Health Organization (WHO)
Project ID: 00098865 00099916	EXTENSION DATE: 30-06-2016 (Phase I)	FINANCIAL COMMITMENTS No cost extension	
Strategic Objective (STEPP) Mission Critical Action MCA3 – Care for persons with Ebola and infection control	PROJECTED END DATE: 30-06-2016 (Phase I) 31-03-2017 (Phase II)	EXPENDITURES as of 30 June 2016 \$ 299,547 (Phase I)	IMPLEMENTING PARTNER(S): Government of Guinea and a team of national and international experts including Italy, UK, US, France and Germany
Location: Guinea	Sub-National Coverage Areas: Basse-Guinée		

¹ The date project funds were first transferred.



UN EBOLA RESPONSE MPTF
PROJECT QUARTERLY PROGRESS REPORT - VERSION 1
Period (Quarter-Year): 2016 (including activities between February and August, 2016)

QUARTERLY PROGRESS REPORT RESULTS MATRIX					
OUTPUT INDICATORS PHASE I					
Indicator	Geographic Area	Projected Target (as per results matrix)	Quantitative results for the quarterly reporting period	Cumulative results since project commencement (quantitative)	Delivery Rate (cumulative % of projected total) as of date
<i>Description of the quantifiable indicator as set out in the approved project proposal</i>					
Number of participants recruited for the initial phase of the vaccination Programme	Guinea	1000	1629	1629	163%
% of blood samples of selected participants systematically collected and analysed at 28 day period	Guinea	100% blood sample collected and analysed at 28 days	78%	78%	78%
EFFECT INDICATORS (if available for the reporting period)					
% of reduction in Ebola disease incidence among the vaccinated group of Survivors and close contacts in Guinea as result of the vaccination programme	Guinea	More than 50%	Not available for the reporting period		



UN EBOLA RESPONSE MPTF
PROJECT QUARTERLY PROGRESS REPORT - VERSION 1
Period (Quarter-Year): 2016 (including activities between February and August, 2016)

OUTPUT INDICATORS PHASE II					
Indicator	Geographic Area	Projected Target (as per results matrix)	Quantitative results for the quarterly reporting period	Cumulative results since project commencement (quantitative)	Delivery Rate (cumulative % of projected total) as of date
<i>Description of the quantifiable indicator as set out in the approved project proposal</i>					
Number of participants recruited for the initial phase of the vaccination Programme	Guinea	1000/1500	2047	2047	204 %
100% of blood samples of selected participants systematically collected and analyzed at 28 day period (includes up to 500 EVD survivors and up to 1500 vaccinees among close contacts of survivors)	Guinea	100% blood sample collected and analyzed at 28 days	638 vaccinated day 28 blood sample collected	638 vaccinated day 28 blood sample collected	73%
100% of contacts of survivors who have consented and received the rVSV vaccine (includes up to up to 1500 vaccinees among close contacts of survivors)	Guinea	100% of contacts of survivors who have consented and received the rVSV vaccine	2047 participants were vaccinated for 2051 consenting participants.	2047 participants were vaccinated for 2051 consenting participants.	99.8%



UN EBOLA RESPONSE MPTF
PROJECT QUARTERLY PROGRESS REPORT - VERSION 1
Period (Quarter-Year): 2016 (including activities between February and August, 2016)

International and Guinea Staff working on Study travel to meet regularly with key stakeholders to review results and provide quarterly reports	Guinea, Liberia and Switzerland	Regular meetings with key stakeholders to review results and provide quarterly reports	Weekly meetings in Guinea with Ebola Coordination, participation to scientific meeting organized in July 2016 in Monrovia and another one organized in Geneva in September 2016	Weekly meetings in Guinea with Ebola Coordination, participation to scientific meeting organized in July 2016 in Monrovia and another one organized in Geneva in September 2016	
--	---------------------------------	--	---	---	--

EFFECT INDICATORS (if available for the reporting period)

% of reduction in Ebola disease incidence among the vaccinated group of Survivors and close contacts in Guinea as result of the vaccination programme	Guinea	More than 50%	Not available for the reporting period		
---	--------	---------------	--	--	--

NARRATIVE

Situation Update & key Achievements

Good clinical practice training was organized from February 11th to 13th. This training also focused on Protocol's SOPs and a specific training on counseling was directed to the teams in charge of survivor's participants.

Recruitment of Ebola survivors and vaccination of their contacts started on 23 May 2016. So far, up until 13 August 2016, a total of 48 survivors have been enrolled in the study with their samples successfully taken.

In addition, 114 rings have been established with a total of 1631 participants recruited among which 1629 contacts of survivors were effectively vaccinated. Each ring having an average of 14.2 participants per ring.

At this date, 87% of participants had been followed up to the day 28 after vaccination to ensure the wellbeing of each participant and to document any potential adverse event. 100% of the blood samples taken as base line on day 0 of vaccination were collected. On the 13th of August 2016, 92 rings on the 114 constituted were still waiting the 28th day to be able to collect the second blood sample. The population of participants which



UN EBOLA RESPONSE MPTF
PROJECT QUARTERLY PROGRESS REPORT - VERSION 1
Period (Quarter-Year): 2016 (including activities between February and August, 2016)

reached day 28 follow up at the time represents 702 people among which 611 people were seen and 549 blood samples were collected. Despite Ramadan’s holy fast period, most of the participants continued their follow up visits and accepted the last blood sampling.

Delays or Deviations

The recruitment of Ebola survivors and vaccination of their contacts started only in May 23rd due to the comments and suggestions from the Ethics Review Committees that needed to be addressed, thus delaying the approvals and the start of the study. Ramadan’s holy fast period as well as rainy season has slowed down the recruitment process but did not had any impact on participant’s follow up rate. The inclusion period of new participants for vaccination stopped at the end of August 2016. The follow up period will last until the end of September 2016.

Gender and Environmental Markers

No. of Beneficiaries	
Women	509
Girls	231
Men	989
Boys	322
Total	2051

Environmental Markers
<i>Non applicable</i>

Additional Information

The budget from this project has served to partially covered the activities and expenses of the cohort study. The additional funds provided in the second grant have been critical to ensure the implementation of this study.